Polymer–drug conjugate therapeutics advances, insights and prospects

Purpose: Polymer–drug conjugates have achieved clinical success, especially PEG–protein conjugates, but translation of many conjugates—particularly polymer–small-molecule anticancer therapeutics—remains limited. This review addresses the need for rational design, better understanding of in vivo barriers, and identification of obstacles to clinical translation.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that conjugation of therapeutic agents to polymeric carriers improves solubilization, circulation, controlled release, and safety, and that rational design—including linker chemistry, architecture, stimuli-responsive functionality, and multifunctional integration—can expand clinical utility.

Aims: Review classes of polymer–drug conjugates: polymer–protein, polymer–small-molecule, dendrimers, and polymer nanoparticles. - Discuss rational design, physicochemical characteristics, linker chemistry, and targeting strategies. - Summarize marketed products and clinical pipeline. - Highlight stimuli-responsive and multifunctional systems for combination therapy and theranostics. - Identify obstacles hampering clinical translation and future prospects.

Delivery system: Carrier polymers: PEG, HPMA copolymers, polyglutamic acid, dextran, polysialic acid, XTEN, PAS, poly(2-oxazoline)s, polypeptides, polycarbonates, poly(glycerol carbonate). - Architectures: Linear, branched, circular, star, dendrimers (PAMAM, poly(L-lysine)), polymeric micelles, core-crosslinked micelles, polymer nanoparticles, dendrimersomes, nanocapsules. - Payloads: Small-molecule drugs (doxorubicin, paclitaxel, irinotecan/SN-38, cisplatin, epirubicin, camptothecin, docetaxel, naloxone), proteins/enzymes (adenosine deaminase, asparaginase, interferons, G-CSF, factor VIII, uricase), peptides, aptamers, and imaging agents. - Linkers: Hydrolytically cleavable esters; acid-sensitive hydrazone, acetal, aconityl; reduction-sensitive disulfide/thioether; enzymatically cleavable peptides (cathepsin B, MMP). - Targeting/functional moieties: Antibodies/Fab′, folate, RGD, aptamers, peptides, imaging agents, and radionuclides.

Approach: Review of preclinical and clinical literature, including marketed products (e.g., Adagen, Oncaspar, PegIntron, Pegasys, Neulasta, Mircera, Cimzia, Movantik), clinical candidates (e.g., PK1, Onzeald, NKTR-214, APL-2, DEP docetaxel, CriPec docetaxel, CRLX101), and animal models (mice, rats, dogs, rabbits). No new primary experiments are reported.

Key methods: Pharmacokinetics: plasma half-life, AUC, clearance, Cmax. - Biodistribution and tumor accumulation: radiolabeling, imaging, gamma counting. - Linker cleavage and drug release kinetics. - Efficacy: tumor growth inhibition, survival, anti-inflammatory activity, immune activation. - Safety: immunogenicity, anti-PEG antibodies, cytotoxicity, haemolysis, toxicity. - Physicochemical characterization: molecular mass, polydispersity, drug loading, architecture, stability.

Key results: Oncaspar: PEG–L-asparaginase half-life extended to 357 h vs 20 h for unmodified enzyme. - Mircera: PEG–epoetin beta half-life 134 h vs <25 h for other ESAs. - PK1: 15-fold improved plasma half-life and 17–77-fold greater tumor accumulation than free doxorubicin, but only 8 of 37 imaged patients showed verifiable tumor uptake. - Onzeald: up to 400-fold increased plasma AUC vs irinotecan; SN-38 elimination half-life 50 days vs 12–47 h. - EPR meta-analysis: on average only 0.7% of intravenously injected dose reaches tumor. - High drug loading: up to 74 wt% paclitaxel in poly(glycerol carbonate) backbone; >100 wt% with additional free drug entrapment. - Movantik: only marketed polymer–small-molecule conjugate (approved 2014).

Interpretation: Polymer–drug conjugation has matured substantially, with PEG–protein conjugates dominating clinical success. Polymer–small-molecule conjugates in oncology have shown limited efficacy benefit, largely because EPR-mediated tumor accumulation is heterogeneous and preclinical models poorly predict human outcomes. Future progress requires rational bottom-up design, biodegradable and biocompatible carriers, optimized linker chemistry, multifunctional and stimuli-responsive systems, combination therapy, theranostics, and better predictive preclinical models.

Limitations: Review, not primary study; no new experimental data or meta-analysis. - PEG and HPMA are non-biodegradable; molecular mass optimization limited by renal clearance threshold. - Anti-PEG antibodies can cause rapid clearance and loss of efficacy. - EPR effect in human tumors is highly variable; tumor accumulation does not guarantee response. - Preclinical models poorly predict clinical pharmacokinetics, biodistribution, and efficacy. - Manufacturing complexity, reproducibility, scalability, and critical quality attributes remain challenging. - Only one polymer–small-molecule conjugate (Movantik) has reached market; no polymer–drug conjugate nanoparticle has reached market to date.